2024
Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service Medicare
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
2020
Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015
Wilson LE, Greiner MA, Altomare I, Rotter J, Dinan MA. Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015. Journal Of Geriatric Oncology 2020, 12: 375-380. PMID: 33250425, DOI: 10.1016/j.jgo.2020.11.007.Peer-Reviewed Original ResearchConceptsProstate cancerCancer costsLung cancerBreast cancerProportion of patientsSystemic anticancer therapyPart D enrollmentNew malignanciesPatients 65Systemic therapyMedicare 5Colorectal cancerInvasive lungMedicare patientsCohort analysisMedicare populationMedicare beneficiariesPatientsSolid tumorsTherapyCancerAnticancer therapyCancer therapyFinancial burdenLung
2017
Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases
Savla B, Ahmed K, Yu M, Perez B, Dinan M, Mason N, Robinson T. Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e105. DOI: 10.1016/j.ijrobp.2017.06.842.Peer-Reviewed Original Research
2015
Nationwide Utilization of Cardiac Imaging in Patients Undergoing External Beam Radiation Therapy With and Without Cardiotoxic Chemotherapy
Dinan M, Li Y, Reed S, Cheung W. Nationwide Utilization of Cardiac Imaging in Patients Undergoing External Beam Radiation Therapy With and Without Cardiotoxic Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e368-e369. DOI: 10.1016/j.ijrobp.2015.07.1487.Peer-Reviewed Original Research
2014
Association Between Diagnostic CT Utilization and Radiation Therapy at the End of Life (EOL) in Elderly Breast and Prostate Cancer Patients: 2002-2007
Dinan M, Curtis L, Setoguchi-Iwata S, Cheung W. Association Between Diagnostic CT Utilization and Radiation Therapy at the End of Life (EOL) in Elderly Breast and Prostate Cancer Patients: 2002-2007. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s582. DOI: 10.1016/j.ijrobp.2014.05.1751.Peer-Reviewed Original ResearchAssociation between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients.
Dinan M, Curtis L, Setoguchi S, Cheung W. Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients. Journal Of Clinical Oncology 2014, 32: 6529-6529. DOI: 10.1200/jco.2014.32.15_suppl.6529.Peer-Reviewed Original Research
2013
Changes in Radiation Therapy, Surgery, and Costs for Treatment of Non-Small Cell Lung Cancer After the Adoption of Positron Emission Tomography: 1998-2005
Dinan M, Curtis L, Carpenter W, Biddle A, Abernethy A, Patz E, Schulman K, Weinberger M. Changes in Radiation Therapy, Surgery, and Costs for Treatment of Non-Small Cell Lung Cancer After the Adoption of Positron Emission Tomography: 1998-2005. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s41-s42. DOI: 10.1016/j.ijrobp.2013.06.110.Peer-Reviewed Original Research
2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerHormonal therapyClinicopathologic characteristicsRisk groupsEarly-stage breast cancerIncremental cost-effectiveness ratioHigh-risk characteristicsLifetime medical costsCost-effectiveness ratioLow-risk characteristicsDecision analytic modelChemotherapy useMedical costsChemotherapyPatientsHealth systemSocietal perspectiveRecurrenceCancerMultifactorial decisionTherapySupportive evidenceTreatment